Skip to content
Menu

Oculis Wins FDA IND Clearance For Privosegtor In Acute MS Relapses, Including Optic Neuritis And Ambulatory Relapses, With Primary Endpoint As Early As Three Months

Benzinga Newsdesk 1 day ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program in optic neuritis

Oculis will host an R&D Day on December 8, 2026, to provide further updates on the development program for Privosegtor in acute MS relapses and the ongoing PIONEER program in optic neuropathies

Read at benzinga.com